News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
540,762 Results
Type
Article (15255)
Company Profile (162)
Press Release (525272)
Multimedia
Podcasts (30)
Webinars (15)
Section
Business (180467)
Career Advice (710)
Deals (27866)
Drug Delivery (37)
Drug Development (61139)
Employer Resources (60)
FDA (11523)
Job Trends (9987)
News (264100)
Policy (23475)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (845)
Accelerated approval (38)
ADA (23)
Adcomms (11)
Allergies (128)
Alliances (36868)
ALS (139)
Alzheimer's disease (1293)
Antibody-drug conjugate (ADC) (375)
Approvals (12044)
Artificial intelligence (472)
ASCO (196)
Autoimmune disease (255)
Automation (40)
Bankruptcy (296)
Best Places to Work (8074)
BIO (47)
BIOSECURE Act (5)
Biosimilars (150)
BioSpace Insights (43)
Biotechnology (102)
Bladder cancer (167)
Brain cancer (47)
Breast cancer (602)
Cancer (4578)
Cardiovascular disease (322)
Career advice (587)
Career pathing (12)
CAR-T (212)
CDC (19)
Celiac Disease (1)
Cell therapy (603)
Cervical cancer (45)
Clinical research (54936)
Collaboration (1567)
Commercialization (3)
Company closure (5)
Compensation (1488)
Complete response letters (68)
COVID-19 (1207)
CRISPR (75)
C-suite (883)
Cystic fibrosis (105)
Data (6707)
Denatured (10)
Depression (130)
Dermatology (75)
Diabetes (429)
Diagnostics (5102)
Digital health (43)
Diversity (5)
Diversity, equity & inclusion (16)
Drug discovery (224)
Drug pricing (48)
Drug shortages (13)
Duchenne muscular dystrophy (254)
Earnings (77836)
Editorial (26)
Employer branding (8)
Employer resources (54)
Events (94923)
Executive appointments (819)
FDA (14641)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (23)
Funding (1212)
Gene editing (156)
Generative AI (23)
Gene therapy (446)
GLP-1 (533)
Government (2587)
Grass and pollen (2)
Guidances (333)
Healthcare (11225)
Hematology (124)
HIV (66)
Huntington's disease (33)
IgA nephropathy (84)
Immunology and inflammation (200)
Immuno-oncology (77)
Indications (185)
Infectious disease (1459)
Inflammatory bowel disease (169)
Inflation Reduction Act (9)
Influenza (105)
Intellectual property (279)
Interviews (109)
IPO (13467)
IRA (12)
Job creations (2304)
Job search strategy (497)
JPM (16)
Kidney cancer (20)
Labor market (20)
Layoffs (191)
Leadership (17)
Legal (6335)
Licensing (8)
Liver cancer (60)
Longevity (22)
Lung cancer (630)
Lymphoma (325)
Machine learning (40)
Management (24)
Manufacturing (686)
Marketing (13)
MASH (159)
Medical device (9536)
Medtech (9692)
Mergers & acquisitions (15530)
Metabolic disorders (989)
mRNA (95)
Multiple sclerosis (142)
NASH (10)
Neurodegenerative disease (298)
Neuropsychiatric disorders (68)
Neuroscience (2430)
NextGen: Class of 2026 (3778)
Non-profit (1688)
Now hiring (16)
Obesity (376)
Opinion (116)
Ovarian cancer (192)
Pain (205)
Pancreatic cancer (254)
Parkinson's disease (263)
Partnered (18)
Patents (542)
Patient recruitment (607)
Peanut (42)
People (44948)
Pharmaceutical (35)
Pharmacy benefit managers (16)
Phase 1 (17541)
Phase 2 (24538)
Phase 3 (17126)
Pipeline (8486)
Policy (112)
Postmarket research (1765)
Preclinical (7431)
Press Release (36)
Prostate cancer (238)
Psychedelics (28)
Radiopharmaceuticals (211)
Rare diseases (824)
Real estate (3418)
Recruiting (23)
Regulatory (18729)
Reports (29)
Research institute (909)
Resumes & cover letters (114)
Rett syndrome (42)
RNA editing (13)
RSV (62)
Schizophrenia (147)
Series A (218)
Series B (156)
Service/supplier (5)
Sickle cell disease (75)
Special edition (9)
Spinal muscular atrophy (109)
Sponsored (17)
Startups (2440)
State (1)
Stomach cancer (8)
Supply chain (68)
Tariffs (27)
The Weekly (20)
Vaccines (518)
Venture capital (43)
Weight loss (186)
Women's health (98)
Worklife (4)
Date
Last 7 days (508)
Last 30 days (1834)
Last 365 days (22436)
2026 (14267)
2025 (22736)
2024 (26447)
2023 (30193)
2022 (38856)
2021 (41842)
2020 (38530)
2019 (28342)
2018 (21541)
2017 (21527)
2016 (20501)
2015 (26714)
2014 (23226)
2013 (19559)
2012 (21773)
2011 (21810)
2010 (21439)
Location
Africa (336)
Alabama (79)
Alaska (4)
Arizona (313)
Arkansas (11)
Asia (22194)
Australia (3091)
California (12814)
Canada (3444)
China (734)
Colorado (507)
Connecticut (462)
Delaware (284)
Europe (39770)
Florida (1853)
Georgia (396)
Hawaii (4)
Idaho (50)
Illinois (848)
India (65)
Indiana (371)
Iowa (14)
Japan (467)
Kansas (122)
Kentucky (35)
Louisiana (28)
Maine (32)
Maryland (1384)
Massachusetts (8544)
Michigan (324)
Minnesota (616)
Mississippi (5)
Missouri (92)
Montana (26)
Nebraska (11)
Nevada (120)
New Hampshire (64)
New Jersey (3042)
New Mexico (15)
New York (2995)
North Carolina (1426)
North Dakota (4)
Northern California (6495)
Ohio (313)
Oklahoma (15)
Oregon (24)
Pennsylvania (2383)
Puerto Rico (22)
Rhode Island (34)
South America (548)
South Carolina (77)
South Dakota (1)
Southern California (5206)
Tennessee (185)
Texas (2049)
United States (42312)
Utah (379)
Vermont (1)
Virginia (197)
Washington D.C. (46)
Washington State (1027)
West Virginia (2)
Wisconsin (111)
Wyoming (2)
540,762 Results for "actio biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
August 10, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Actio Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
·
1 min read
Press Releases
Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process
May 8, 2026
·
5 min read
Press Releases
Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity
December 8, 2025
·
4 min read
Press Releases
Actio Biosciences to Participate in TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 11, 2025
·
1 min read
Press Releases
Actio Biosciences to Participate in Evercore Emerging Private Biotech Conference
July 7, 2025
·
1 min read
Press Releases
Actio Biosciences to Present New Preclinical Data for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy, at the American Epilepsy Society Annual Meeting
November 25, 2025
·
3 min read
Press Releases
Actio Biosciences to Participate in Piper Sandler Spring Biopharma Symposium
April 9, 2025
·
1 min read
Business
Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors
Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors.
May 22, 2024
·
2 min read
Press Releases
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
September 24, 2025
·
3 min read
1 of 54,077
Next
